Survival Outcomes and Toxicity of Adjuvant Immunotherapy After Definitive Concurrent Chemotherapy with Proton Beam Radiation Therapy for Patients with Inoperable Locally Advanced Non-small Cell Lung Carcinoma

Overview

Journal Radiother Oncol

Specialties Oncology
Radiology

Date 2024 Feb 4

PMID 38311031

Authors

Kelsey L Corrigan

Ting Xu

Yuki Sasaki

Ruitao Lin

Aileen B Chen

James W Welsh

Steven H Lin

Joe Y Chang

Matthew S Ning

Saumil Gandhi

Michael S OReilly

Carl M Gay

Mehmet Altan

Charles Lu

Tina Cascone

Efstratios Koutroumpakis

Ajay Sheshadri

Xiaodong Zhang

Li Liao

X Ronald Zhu

John V Heymach

Quynh-Nhu Nguyen

Zhongxing Liao

Affiliations

Soon will be listed here.

Abstract

Introduction: Adjuvant immunotherapy (IO) following concurrent chemotherapy and photon radiation therapy confers an overall survival (OS) benefit for patients with inoperable locally advanced non-small cell lung carcinoma (LA-NSCLC); however, outcomes of adjuvant IO after concurrent chemotherapy with proton beam therapy (CPBT) are unknown. We investigated OS and toxicity after CPBT with adjuvant IO versus CPBT alone for inoperable LA-NSCLC.

Materials And Methods: We analyzed 354 patients with LA-NSCLC who were prospectively treated with CPBT with or without adjuvant IO from 2009 to 2021. Optimal variable ratio propensity score matching (PSM) matched CPBT with CPBT + IO patients. Survival was estimated with the Kaplan-Meier method and compared with log-rank tests. Multivariable Cox proportional hazards regression evaluated the effect of IO on disease outcomes.

Results: Median age was 70 years; 71 (20%) received CPBT + IO and 283 (80%) received CPBT only. After PSM, 71 CPBT patients were matched with 71 CPBT + IO patients. Three-year survival rates for CPBT + IO vs CPBT were: OS 67% vs 30% (P < 0.001) and PFS 59% vs 35% (P = 0.017). Three-year LRFS (P = 0.137) and DMFS (P = 0.086) did not differ. Receipt of adjuvant IO was a strong predictor of OS (HR 0.40, P = 0.001) and PFS (HR 0.56, P = 0.030), but not LRFS (HR 0.61, P = 0.121) or DMFS (HR 0.61, P = 0.136). There was an increased incidence of grade ≥3 esophagitis in the CPBT-only group (6% CPBT + IO vs 17% CPBT, P = 0.037).

Conclusion: This study, one of the first to investigate CPBT followed by IO for inoperable LA-NSCLC, showed that IO conferred survival benefits with no increased rates of toxicity.

References

Shiraishi Y, Fang P, Xu C, Song J, Krishnan S, Koay E . Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. Radiother Oncol. 2017; 128(1):154-160. PMC: 5999560. DOI: 10.1016/j.radonc.2017.11.028. View

Ellsworth S . Field size effects on the risk and severity of treatment-induced lymphopenia in patients undergoing radiation therapy for solid tumors. Adv Radiat Oncol. 2018; 3(4):512-519. PMC: 6200885. DOI: 10.1016/j.adro.2018.08.014. View

Mohan R, Grosshans D . Proton therapy - Present and future. Adv Drug Deliv Rev. 2016; 109:26-44. PMC: 5303653. DOI: 10.1016/j.addr.2016.11.006. View

Mirjolet C, Nicol A, Limagne E, Mura C, Richard C, Morgand V . Impact of proton therapy on antitumor immune response. Sci Rep. 2021; 11(1):13444. PMC: 8241828. DOI: 10.1038/s41598-021-92942-1. View

Jing W, Xu T, Wu L, Lopez P, Grassberger C, Ellsworth S . Severe Radiation-Induced Lymphopenia Attenuates the Benefit of Durvalumab After Concurrent Chemoradiotherapy for NSCLC. JTO Clin Res Rep. 2022; 3(9):100391. PMC: 9449658. DOI: 10.1016/j.jtocrr.2022.100391. View

Austin P . An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res. 2011; 46(3):399-424. PMC: 3144483. DOI: 10.1080/00273171.2011.568786. View

Ming K, Rosenbaum P . Substantial gains in bias reduction from matching with a variable number of controls. Biometrics. 2000; 56(1):118-24. DOI: 10.1111/j.0006-341x.2000.00118.x. View

Mellman I, Coukos G, Dranoff G . Cancer immunotherapy comes of age. Nature. 2011; 480(7378):480-9. PMC: 3967235. DOI: 10.1038/nature10673. View

Liao Z, Komaki R, Thames Jr H, Liu H, Tucker S, Mohan R . Influence of technologic advances on outcomes in patients with unresectable, locally advanced non-small-cell lung cancer receiving concomitant chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009; 76(3):775-81. DOI: 10.1016/j.ijrobp.2009.02.032. View

10.

Fitzgerald K, Simone 2nd C . Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer. Thorac Surg Clin. 2020; 30(2):221-239. DOI: 10.1016/j.thorsurg.2020.01.002. View

11.

Liu H, Wang X, Dong L, Wu Q, Liao Z, Stevens C . Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2004; 58(4):1268-79. DOI: 10.1016/j.ijrobp.2003.09.085. View

12.

Campian J, Ye X, Brock M, Grossman S . Treatment-related lymphopenia in patients with stage III non-small-cell lung cancer. Cancer Invest. 2013; 31(3):183-8. PMC: 4596242. DOI: 10.3109/07357907.2013.767342. View

13.

Chun S, Hu C, Choy H, Komaki R, Timmerman R, Schild S . Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol. 2016; 35(1):56-62. PMC: 5455690. DOI: 10.1200/JCO.2016.69.1378. View

14.

Jing W, Liu Y, Zhu H, Welsh J, Gandhi S, Jeter M . Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. Clin Transl Radiat Oncol. 2021; 28:54-61. PMC: 7985216. DOI: 10.1016/j.ctro.2021.02.011. View

15.

Liao Z, Lee J, Komaki R, Gomez D, OReilly M, Fossella F . Bayesian Adaptive Randomization Trial of Passive Scattering Proton Therapy and Intensity-Modulated Photon Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. J Clin Oncol. 2018; 36(18):1813-1822. PMC: 6008104. DOI: 10.1200/JCO.2017.74.0720. View

16.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

17.

Tang C, Liao Z, Gomez D, Levy L, Zhuang Y, Gebremichael R . Lymphopenia association with gross tumor volume and lung V5 and its effects on non-small cell lung cancer patient outcomes. Int J Radiat Oncol Biol Phys. 2014; 89(5):1084-1091. DOI: 10.1016/j.ijrobp.2014.04.025. View

18.

Asmis T, Ding K, Seymour L, Shepherd F, Leighl N, Winton T . Age and comorbidity as independent prognostic factors in the treatment of non small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008; 26(1):54-9. DOI: 10.1200/JCO.2007.12.8322. View

19.

Patrinely Jr J, Johnson R, Lawless A, Bhave P, Sawyers A, Dimitrova M . Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-risk Resected Melanoma. JAMA Oncol. 2021; 7(5):744-748. PMC: 7995124. DOI: 10.1001/jamaoncol.2021.0051. View

20.

Zhu C, Mohan R, Lin S, Jun G, Yaseen A, Jiang X . Identifying Individualized Risk Profiles for Radiotherapy-Induced Lymphopenia Among Patients With Esophageal Cancer Using Machine Learning. JCO Clin Cancer Inform. 2021; 5:1044-1053. PMC: 8812653. DOI: 10.1200/CCI.21.00098. View